Anthem’s Board Adds Jallal as Director

Bahija Jallal

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Anthem Inc. has added Bahija Jallal, PhD, to its board of directors. With more than 25 years of leadership experience and expertise in the biopharmaceutical industry, Jallal’s science-driven leadership combined with her passion to improve the lives of patients will be an asset to the board.

She currently serves as executive vice president of AstraZeneca and president of its biotechnology subsidiary MedImmune, where she is responsible for biologics research and development activities and advancing the biologics portfolio of medicines.

Under her leadership, MedImmune has seen an unprecedented expansion of its pipeline, including three US Food and Drug Administration approvals in 2017. Today, the company has more than 130 biologics in research and development and 40 products in clinical development. Her vision to instill an entrepreneurial culture and mindset across the organization led AstraZeneca to establish one of its research and development hubs at MedImmune’s headquarters, positioning MedImmune as the biologics transformation engine driving AstraZeneca.

Prior to joining AstraZeneca, Jallal served as vice president for drug assessment and development at Chiron Corp.; before that she was senior director of research at Sugen Inc., a subsidiary of Pfizer.